Ladenburg Thalmann Financial Services restated their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report released on Thursday morning. The brokerage currently has a $146.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $90.00.

ALNY has been the topic of several other research reports. Needham & Company LLC restated a buy rating and set a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Chardan Capital restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 11th. Nomura started coverage on Alnylam Pharmaceuticals in a report on Thursday, September 14th. They set a reduce rating and a $56.00 target price on the stock. ValuEngine upgraded Alnylam Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, June 2nd. Finally, Instinet started coverage on Alnylam Pharmaceuticals in a report on Friday, September 15th. They set a reduce rating and a $56.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $93.11.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 113.80 on Thursday. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $118.40. The firm’s market cap is $10.44 billion. The company has a 50-day moving average of $81.14 and a 200 day moving average of $69.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s revenue was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.05) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/25/alnylam-pharmaceuticals-inc-alny-rating-reiterated-by-ladenburg-thalmann-financial-services.html.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $148,000. QS Investors LLC raised its position in shares of Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 900 shares during the period. Westpac Banking Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $202,000. The Manufacturers Life Insurance Company raised its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $215,000. 94.25% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.